Skip to content

Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections

Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02650518
Acronym
CARCUTI
Enrollment
500
Registered
2016-01-08
Start date
2015-12-31
Completion date
2018-10-31
Last updated
2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-Related Infections

Keywords

Catheter-Associated Urinary Tract Infections, Antimicrobial Stewardship, Short-Course Antimicrobials

Brief summary

Hypothesis: A short course (3-5 days) of antibiotic therapy (experimental arm) is as safe and effective as a long course of antibiotic therapy for the treatment of catheter-associated urinary tract infections.

Interventions

OTHERShort-course Antibiotics

3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.

Urinary catheter change once randomization is complete.

Sponsors

Tan Tock Seng Hospital
CollaboratorOTHER
Singapore General Hospital
CollaboratorOTHER
National University of Singapore
CollaboratorOTHER
National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Inpatients ≥ 21 years old. 2. Presence of indwelling urinary catheter at the time of urine culture for ≥2days. 3. Fever \>38°C. 4. A urine specimen sent to the hospital microbiological laboratory for culture. 5. An antibiotic order for presumed symptomatic catheter associated urinary tract infection.

Exclusion criteria

1. Persistent fever \>38°C for more than 24 hours, or any fever \>38.9°C. 2. Haemodynamic instability, defined as: * Requirement for intravenous vasopressor agents * Systolic blood pressure \<90 mmHg * Acute hypotensive event with drop in systolic blood pressure of \>30 mmHg or diastolic blood pressure of \>20 mmHg 3. The following laboratory values within the previous 48 hours (if available): * White blood cell count\>15 or \<4 x10\^9/L. * Procalcitonin\>0.25ug/mL * C Reactive Protein \>100mg/mL * An increase in the serum creatinine of more than 50% from baseline 4. New requirement for oxygen supplement. 5. Current admission to a high dependency unit or ICU. 6. Radiological evidence of an upper urinary tract infection 7. Flank pain or tenderness, suggesting an upper urinary tract infection 8. Urologic surgical procedure within the previous 72 hours 9. Known structural genitourinary abnormalities including: * Nephrostomy tubes * Tumours of the urinary tract * Ureteric stenting * Ureteric strictures * Urolithiasis 10. Bloodstream or other significant infection suspected at any site other than the catheterized urinary tract. 11. Received antibiotics for more than 48 hours prior to randomization. 12. Positive urinary culture with organism resistant to all the investigational antibiotics in the week prior to randomisation. 13. Hypersensitivity to ciprofloxacin, cotrimoxazole and amoxicillin-clavulanate. 14. Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
ResolutionDay 14 post-randomisationResolution of signs and symptoms of CAUTI

Secondary

MeasureTime frameDescription
Recurrence of fever or symptoms7, 14 and 30 days post randomization
Haemodynamic instabilityday 14 post randomization
Admission to high dependency or intensive care units14 days post-randomization
Length of hospitalization30 days post-randomization
Re-admissionDay 30 post-randomization
Short-Term Resolutionday 3 and day 7 post-randomisationResolution of signs and symptoms of CAUTI
Recurrent Urinary Tract Infections3 months and 1 year post-randomization
Urologic surgery or procedure1 year post-randomization
Antimicrobial use and duration1 month post-randomization
Colonization or infection by antibiotic-resistant organisms30 days post-randomization
Secondary Infections3 months post-randomization

Countries

Singapore

Contacts

Primary ContactPaul A Tambyah, MD
paul_anantharajah_tambyah@nuhs.edu.sg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026